Ocata Therapeutics to be acquired By: MarketMinute.com Stock News November 10, 2015 at 13:27 PM EST Astellas Pharma will pay a premium of $8.50 per share in cash to acquire Ocata Therapeutics Inc. (Nasdaq: OCAT) sending the stock price soaring $3.98 to $8.44.